NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Great question, and while I certainly can't speak for the company, I'll try to explain this in short order.

NWBO's first nonspecific tumor lysate platform product was/is DCVAX-Brain (aka:DCVAX-L). Since 1999, it has been tested on GBM patients. It is administered sub-dermally.

The results for DCVAX-L are most notably measured by 'overall survival' (OS) and progression free survival (PFS). In the case of DCVAX-L, Provenge, ICT-107 as well as other dendritic technologies, the influence on OS and PFS becomes more evident 2-5 years after treatment when compared with control groups and/or historical standards. This is what is known as the "Long Tail."

So when NWBO's PR from today states,

"Immune therapies generally work much more slowly than chemotherapy or targeted drugs, so it is especially encouraging to see any such signs so soon…."

What they are really talking about are immune therapies like DCVAX-L, Provenge and ICT-107.

So, when NWBO first announced the DCVAX-Direct trial and stated, "tumor regression, if it happens, will be seen within the first few months of injection…." They were talking about their latest and best technology expectation -- DCVAX-Direct. These folks have been working on the L trial forever, so they are, in not so many words, trying to point out what an amazing breakthrough this is!!! From Long Tail to Short Nose….

Well, you get the picture.